IMV Inc. is a clinical-stage pharmaceutical company developing an effective T cell-targeted immune therapy for cancer. The company has built a delivery platform (DPX) that generates targeted immune cells directly into the human body, which produces robust and sustained capabilities to destroy cancer.
Its lead drug candidate, Maveropepimut-S (DPX-Survivac), which has completed multiple Phase 1/1b trials successfully, has generated positive results in advanced recurrent ovarian cancer and Diffuse Large B Cell Lymphoma (DLBCL).
IMV's DPX Platform enables antigen-presenting cells (APCs) to be attracted to the injection site, facilitating antigen presentation to immune cells. All IMV's immunotherapies and vaccines candidates are formulated with the DPX platform, giving them the ability to generate, in vivo, a targeted, robust, and sustained immune response against cancer cells or viruses.
The company is partnering with pharmaceutical companies, government agencies, and academic research institutions for the purpose of research and development.
According to a press release from the company, IMV has made "significant progress" in its COVID-19 vaccine development efforts.